Hippocampal astrocytes in juvenile rats with persistent epilepsy: the role of cannabinoid receptor type 2 in regulating MAPK pathway

doi:10.3969/j.issn.2095-4344.2868

Abstract

Abstract:

BACKGROUND: Astrocyte proliferation is an important morphological change in epilepsy. Proliferated glial cells can produce cytokines, and in turn activates JAK/STAT signal transduction to promote glial cell proliferation, which affects the occurrence and recurrence of epilepsy. Astrocytes and signal transduction pathways interact with each other to play a role in the pathogenesis of epilepsy.

OBJECTIVE: To investigate the effect of cannabinoid receptor type 2 (CB2R) on the activation of ERK, p38, and JNK proteins in astrocytes and MAPK pathways in juvenile rats with persistent epilepsy.

METHODS: Forty healthy male Sprague-Dawley rats (18-21 days old) were randomly divided into four groups: normal control group, epilepsy model group, CB2R agonist JWH133 group, CB2R antagonist AM630 group. The normal control group was given only normal saline. In the other groups, rats were intraperitoneally injected with lithium chloride and pilocarpine to establish epilepsy models, and different interventions were performed. Twenty-four hours after the onset of epilepsy, brain tissues were taken. Co-expression of GFAP and p-ERK, p-p38, and p-JNK in hippocampal tissue was detected by immunofluorescence. Real-time PCR was used to detect the expression of GFAP mRNA in hippocampal tissue.

RESULTS AND CONCLUSION: The co-expression of GFAP/p-ERK and GFAP/p-p38 was significantly higher in the epilepsy model group than the normal control group (P < 0.05), significantly lower in the JWH133 group than the epilepsy model group (P < 0.05), and significantly higher in the AM630 group than the JWH133 group (P < 0.05). The co-expression of GFAP/p-JNK was significantly lower in the epilepsy model group than in normal control group (P < 0.05), significantly higher in the JWH133 group than the epilepsy model group (P < 0.05), and significantly lower in the AM630 group than the JWH133 group (P < 0.05). The mRNA expression of GFAP was significantly decreased in the epilepsy model group compared with the normal control group (P < 0.05), significantly increased in the JWH133 group compared with the epilepsy model group (P < 0.05), and significantly reduced in the AM630 group compared with the JWH133 group (P < 0.05). Therefore, CB2R can regulate the expression of ERK, p38, JNK proteins in the MAPK pathway, thereby affecting astrocytes in the hippocampus of juvenile rats with persistent epilepsy.

Key words: cannabinoid receptor type 2, status epilepticus, astrocytes, MAPK pathway, juvenile rats, experiment

CLC Number:

Cao Qingjun, Yang Fenghua, Wang Hua. Hippocampal astrocytes in juvenile rats with persistent epilepsy: the role of cannabinoid receptor type 2 in regulating MAPK pathway[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(32): 5179-5185.

Figures/Tables 9

References

[1] DANZER SC. Contributions of Adult-Generated Granule Cells to Hippocampal Pathology in Temporal Lobe Epilepsy: A Neuronal Bestiary. Brain Plast. 2018;3(2):169-181.

[2] MOSHÉ SL, PERUCCA E, RYVLIN P, et al. Epilepsy: new advances. Lancet. 2015;385(9971):884-898.

[3] CHO CH. New mechanism for glutamate hypothesis in epilepsy. Front Cell Neurosci. 2013;7:127.

[4] LIANG J, CHAO D, SANDHU HK, et al. δ-Opioid receptors up-regulate excitatory amino acid transporters in mouse astrocytes. Br J Pharmacol. 2014;171(23):5417-5430.

[5] BIZIÈRE K, CHAMBON JP. Animal models of epilepsy and experimental seizures. Rev Neurol(Paris). 1987;143(5): 329-340.

[6] JANSZKY J, TÉNYI D, BÓNÉ B. Valproate in the treatment of epilepsy and status epilepticus. Ideggyogy Sz. 2017;70(7-8): 258-264.

[7] MASLIAH-PLANCHON J, GARINET S, PASMANT E. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget. 2016;7(25):38892-38907.

[8] LAKE D, CORRÊA SA, MÜLLER J. Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci. 2016;73(23):4397-4413.

[9] RAUCH N, RUKHLENKO OS, KOLCH W, et al. MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. Curr Opin Struct Biol. 2016;41:151-158.

[10] FISHER RS. Animal models of the epilepsies. Brain Res Brain Res Rev. 1989;14(3):245-278.

[11] BRODIE MJ, ELDER AT, KWAN P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019-1030.

[12] LAZAROWSKI A, CZORNYJ L. Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions. Drug Metabol Drug Interact. 2011;26(1):21-26.

[13] MINJAREZ B, CAMARENA HO, HARAMATI J, et al. Behavioral changes in models of chemoconvulsant-induced epilepsy: A review. Neurosci Biobehav Rev. 2017;83:373-380.

[14] LEE M, CHOI BY, SUH SW. Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure- Induced Neuronal Death. Curr Neuropharmacol. 2018;16(1):51-58.

[15] KANDRATAVICIUS L, BALISTA PA, LOPES-AGUIAR C, et al. Animal models of epilepsy: use and limitations. Neuropsychiatr Dis Treat. 2014;10:1693-1705.

[16] SAUVANT C, NOWAK M, WIRTH C, et al. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int J Cancer. 2008;123(11):2532-2542.

[17] COPPOLA G, AURICCHIO G, FEDERICO R, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia. 2004;45(9): 1049-1053.

[18] REGESTA G, TANGANELLI P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res.1999;34(2-3): 109-122.

[19] BORST P, EVERS R, KOOL M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92(16):1295-1302.

[20] CÁRCEL-TRULLOLS J, KOVÁCS AD, PEARCE DA. Cell biology of the NCL proteins: What they do and don't do. Biochim Biophys Acta. 2015;1852(10 Pt B):2242-2255.

[21] EID T, LEE TW, PATRYLO P, et al. Astrocytes and Glutamine Synthetase in Epileptogenesis. J Neurosci Res. 2019;97(11): 1345-1362.

[22] KOZELA E, JUKNAT A, VOGEL Z. Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. Int J Mol Sci. 2017;18(8): E1669.

[23] WIXEY JA, CHAND KK, COLDITZ PB, et al. Review: Neuroinflammation in intrauterine growth restriction. Placenta. 2017;54:117-124.

[24] NAVARRO G, BORROTO-ESCUELA DO, FUXE K, et al. Purinergic signaling in Parkinson's disease. Relevance for treatment. Neuropharmacology. 2016;104:161-168.

[25] MILOSO M, SCUTERI A, FOUDAH D, et al. MAPKs as mediators of cell fate determination: an approach to neurodegenerative diseases. Curr Med Chem. 2008;15(6): 538-548.

[26] ZIEMBA BP, BURKE JE, MASSON G, et al. Regulation of PI3K by PKC and MARCKS: Single-Molecule Analysis of a Reconstituted Signaling Pathway. Biophys J. 2016;110(8): 1811-1825.

[27] KANNER AM, MEADOR KJ. Remember…there is more to epilepsy than seizures! Neurology. 2015;85(13):1094-1095.

[28] MAC TL, TRAN DS, QUET F, et al. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. Lancet Neurol. 2007;6(6):533-543.

[29] HUANG Y, LIU X, LIAO Y, et al. MiR-181a influences the cognitive function of epileptic rats induced by pentylenetetrazol. Int J Clin Exp Pathol. 2015;8(10):12861-12868.

[30] ZHANG C, HOU D, FENG X. Mir-181b Functions as Anti-Apoptotic Gene in Post-Status Epilepticus via Modulation of Nrarp and Notch Signaling Pathway. Ann Clin Lab Sci. 2015;45(5):550-555.

[31] YU PM, DING D, ZHU GX, et al. International Bureau for Epilepsy survey of children, teenagers, and young people with epilepsy: data in China. Epilepsy Behav. 2009;16(1):99-104.

[32] SRIVASTAVA A, DIXIT AB, BANERJEE J, et al. Role of inflammation and its miRNA based regulation in epilepsy: Implications for therapy. Clin Chim Acta. 2016;452:1-9.

[33] ZHENG H, TANG R, YAO Y, et al. MiR-219 Protects Against Seizure in the Kainic Acid Model of Epilepsy. Mol Neurobiol. 2016;53(1):1-7.

[34] CUI L, TAO H, WANG Y, et al. A functional polymorphism of the microRNA-146a gene is associated with susceptibility to drug-resistant epilepsy and seizures frequency. Seizure. 2015; 27:60-65.

[35] LORIGADOS PEDRE L, MORALES CHACÓN LM, OROZCO SUÁREZ S, et al. Inflammatory mediators in epilepsy. Curr Pharm Des. 2013;19(38):6766-6772.

[36] CHEN Y, LIU T, LANGFORD P, et al. Haemophilus parasuis induces activation of NF-κB and MAP kinase signaling pathways mediated by toll-like receptors. Mol Immunol. 2015; 65(2):360-366.

[37] OHNO Y. Astrocytic Kir4.1 potassium channels as a novel therapeutic target for epilepsy and mood disorders. Neural Regen Res. 2018;13(4):651-652.

[38] XU JJ, DIAZ P, BIE B, et al. Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy. Neuroscience. 2014;260:185-194.

[39] BALENGA NA, MARTÍNEZ-PINILLA E, KARGL J, et al. Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling. Br J Pharmacol.2014;171(23): 5387-5406.

[40] SU SH, WU YF, LIN Q, et al. Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 suppress chronic cerebral hypoperfusion-induced neuronal apoptosis by inhibiting c-Jun N-terminal kinase signaling. Neuroscience. 2015;301:563-575.

[41] WANG ZY, WANG P, BJORLING DE. Activation of cannabinoid receptor 2 inhibits experimental cystitis. Am J Physiol Regul Integr Comp Physiol. 2013;304(10):R846-853.